Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Coca-Cola Q4 Earnings Preview: Weighing Iconic Brand Strength Against Health Trends, Weight Loss Drug Impact

Published 12/02/2024, 16:32
Updated 12/02/2024, 17:41
© Reuters.  Coca-Cola Q4 Earnings Preview: Weighing Iconic Brand Strength Against Health Trends, Weight Loss Drug Impact

Benzinga - by Surbhi Jain, .

Coca-Cola Co (NYSE:KO), will be reporting its fourth-quarter earnings on Feb. 13. Wall Street expects 49 cents in EPS and $10.64 billion in revenues as the company reports before market hours.

The company is known for being one of the most popular and iconic soft drink brands in the world. Created by John Stith Pemberton in 1886, Coca-Cola has become a global beverage phenomenon. It represents the fourth-largest holding in Warren Buffett‘s Berkshire Hathaway portfolio, with a 7.05% stake. As a result, Buffett holds 9.23% of Coca-Cola’s stock.

Here are the areas of focus for analysts in the company’s Q4 earnings report, and how the stock measures up against Wall Street forecasts.

Coca-Cola Investment Thesis Coca-Cola boasts a high brand value and a diversified portfolio of beverages, providing resilience against market fluctuations and the challenges faced in 2020 due to the pandemic. The company’s ability to generate profits through licensing its trademark to beverage manufacturers enhances its revenue streams and profitability. It also has a history of rising dividend payouts.

Despite facing challenges, Coca-Cola maintains a stable market share in North America, its largest market.

The rising demand for healthier and more natural products poses a challenge to Coca-Cola’s traditional sugary and less nutritious beverage offerings. However, the company’s strategic investments in healthier segments may mitigate this risk.

The emergence of weight loss drugs, such as Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro, poses a potential threat to Coca-Cola’s business. These drugs may lead to reduced demand for high-calorie or unhealthy beverages.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Also Read: How To Earn $500 Per Month From Coca-Cola Stock (NYSE:KO)

Coca-Cola Analysts' Focus & Consensus Ratings Q4 Analysts' Focus: Analysts will be carefully evaluating the potential impact of evolving consumer preferences and competition from weight loss drugs on Coca-Cola’s business. Coca-Cola’s strong brand value, stable market position, history of dividends, and adaptability are positive indicators to an investor evaluating the business.

However, potential threats underscore the importance of thorough risk assessment and ongoing evaluation of Coca-Cola’s strategy in navigating these challenges.

Ratings & Consensus Estimates: The consensus analyst rating on Coca-Cola stock stands at an Overweight currently with a price target of $66.95.

KO Price Action: Shares of Coca-Cola were trading 0.6% lower at $59.20 at the time of publication Monday.

Read Next: Coca-Cola Dives Into Alcoholic Beverages with Lemon-Dou Pilot In India

Photo: Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.